** Shares of biopharma firm Travere Therapeutics TVTX.O rise 3.5% to $20.42
** TVTX says it submitted a marketing application to the U.S. FDA for co's drug, Filspari, for treatment of a rare kidney scarring disease called focal segmental glomerulosclerosis
** Co expects to receive regulatory decision in Q2
** Filspari is currently approved to slow decline in kidney function in adults with immunoglobulin A nephropathy, a leading cause of kidney failure
** Up to last close, TVTX has more than doubled in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.